secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-266973
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Q3 2025 net loss $5.5M; adjusted EBITDA $2.5M; revenue +2% to $52.3M
--------------------------------------------------------------------------

- Total revenue $52.3M, +2% YoY; installed base 3,456 instruments (+161 units in Q3).
- GAAP net loss $5.5M vs net income $0.9M in Q3 2024; GAAP gross margin 53% vs 56%.
- Adjusted EBITDA $2.5M vs $7.6M in prior year; ex-investment income $0.5M vs $5.7M.
- Recurring revenue up 19% YoY; biopharma/CRO revenue up 14% YoY.
- FY2025 revenue guidance reaffirmed $196M-$205M (-2% to +2% growth).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312525266973/0001193125-25-266973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312525266973/d161249d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-266973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer